<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897792</url>
  </required_header>
  <id_info>
    <org_study_id>F101108001</org_study_id>
    <nct_id>NCT01897792</nct_id>
  </id_info>
  <brief_title>Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma</brief_title>
  <official_title>Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of antioxidant vitamins (vitamins C and
      E) on the development of coagulation derangements and nosocomial pneumonia after severe
      trauma in patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit patients that meet inclusion criteria.
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Coagulation Abnormalities</measure>
    <time_frame>From enrollment up to 3 days</time_frame>
    <description>Coagulation parameters are evaluated using standard functional tests (prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen and platelet count)and point of care functional analysis using thromboelastogram (TEG-ROTEM). A blood sample is collected upon arrival in the emergency department at 0 hours only and analyzed for markers of activation of coagulation, inflammation, and levels of vitamin C/E.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Ventilator-associated Pneumonia.</measure>
    <time_frame>From enrollment to 3 days</time_frame>
    <description>Number of subjects diagnosed with pneumonia and requiring ventilator support.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Organ Injury</measure>
    <time_frame>From enrollment to 3 days</time_frame>
    <description>Any injury to internal organs (thoracic, abdominal or cranial cavity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Total Blood Product Transfusions</measure>
    <time_frame>From enrollment to 3 days</time_frame>
    <description>the number of blood product transfusions for all subjects in each group over the course of 3 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Protocol Violations Per Arm.</measure>
    <time_frame>from enrollment up to 60 days post enrollment</time_frame>
    <description>The number of times that there was a deviation or violation from how the protocol was to be implemented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Surviving to Day 28</measure>
    <time_frame>from enrollment up to 28 days post enrollment</time_frame>
    <description>Number of subjects that survived to day 28 after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With 60-day Survival</measure>
    <time_frame>from enrollment up to 60 days post enrollment</time_frame>
    <description>Number of subjects in each arm that survived to day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Ventilator-free Days for Subjects</measure>
    <time_frame>from enrollment up to 60 days post enrollment</time_frame>
    <description>The mean number of ventilator free days (not on ventilator) for subjects in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days in ICU.</measure>
    <time_frame>from enrollment up to 60 days post enrollment</time_frame>
    <description>the mean number of days each subject was in the ICU in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Hospital Stay Days.</measure>
    <time_frame>from enrollment up to 60 days post enrollment</time_frame>
    <description>The mean number of days subjects were in the hospital in each arm of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Coagulopathy</condition>
  <condition>Nosocomial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Vitamins C and E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% saline and sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <arm_group_label>Vitamins C and E</arm_group_label>
    <other_name>ascorbic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <arm_group_label>Vitamins C and E</arm_group_label>
    <other_name>alpha-tocopherol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saline (for Vitamin C)</intervention_name>
    <description>0.9% saline administered to mimic Vitamin C</description>
    <arm_group_label>0.9% saline and sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Vitamin E)</intervention_name>
    <description>Sugar pill administered to mimic Vitamin E</description>
    <arm_group_label>0.9% saline and sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult trauma patients admitted to the emergency department at the University of
             Alabama at Birmingham (UAB) Hospital

          -  Blunt or penetrating injury

          -  UAB highest trauma activation

        Exclusion Criteria:

          -  Age &lt; 19 years of age

          -  Patients with known bleeding diathesis or who are concurrently taking anticoagulant
             medication

          -  Patients with known liver disease

          -  Minor patients

          -  Pregnant patients (known or suspected pregnancy)

          -  Patients who are incarcerated

          -  Patients who lack a surrogate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Pittet, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Kerby, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg. 2007 May;245(5):812-8.</citation>
    <PMID>17457176</PMID>
  </reference>
  <reference>
    <citation>Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008 May;64(5):1211-7; discussion 1217. doi: 10.1097/TA.0b013e318169cd3c.</citation>
    <PMID>18469643</PMID>
  </reference>
  <reference>
    <citation>Chesebro BB, Rahn P, Carles M, Esmon CT, Xu J, Brohi K, Frith D, Pittet JF, Cohen MJ. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock. 2009 Dec;32(6):659-65. doi: 10.1097/SHK.0b013e3181a5a632.</citation>
    <PMID>19333141</PMID>
  </reference>
  <reference>
    <citation>Cohen MJ, Bir N, Rahn P, Dotson R, Brohi K, Chesebro BB, Mackersie R, Carles M, Wiener-Kronish J, Pittet JF. Protein C depletion early after trauma increases the risk of ventilator-associated pneumonia. J Trauma. 2009 Dec;67(6):1176-81. doi: 10.1097/TA.0b013e3181c1c1bc.</citation>
    <PMID>20009664</PMID>
  </reference>
  <reference>
    <citation>Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg. 2002 Dec;236(6):814-22.</citation>
    <PMID>12454520</PMID>
  </reference>
  <reference>
    <citation>Collier BR, Giladi A, Dossett LA, Dyer L, Fleming SB, Cotton BA. Impact of high-dose antioxidants on outcomes in acutely injured patients. JPEN J Parenter Enteral Nutr. 2008 Jul-Aug;32(4):384-8. doi: 10.1177/0148607108319808.</citation>
    <PMID>18596309</PMID>
  </reference>
  <reference>
    <citation>Secor D, Li F, Ellis CG, Sharpe MD, Gross PL, Wilson JX, Tyml K. Impaired microvascular perfusion in sepsis requires activated coagulation and P-selectin-mediated platelet adhesion in capillaries. Intensive Care Med. 2010 Nov;36(11):1928-34. doi: 10.1007/s00134-010-1969-3. Epub 2010 Aug 6.</citation>
    <PMID>20689935</PMID>
  </reference>
  <reference>
    <citation>Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003 Jun;54(6):1127-30.</citation>
    <PMID>12813333</PMID>
  </reference>
  <reference>
    <citation>MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003 Jul;55(1):39-44.</citation>
    <PMID>12855879</PMID>
  </reference>
  <reference>
    <citation>Esmon CT. The protein C pathway. Chest. 2003 Sep;124(3 Suppl):26S-32S. Review.</citation>
    <PMID>12970121</PMID>
  </reference>
  <reference>
    <citation>Giladi AM, Dossett LA, Fleming SB, Abumrad NN, Cotton BA. High-dose antioxidant administration is associated with a reduction in post-injury complications in critically ill trauma patients. Injury. 2011 Jan;42(1):78-82. doi: 10.1016/j.injury.2010.01.104. Epub 2010 Feb 10.</citation>
    <PMID>20149369</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>October 27, 2015</results_first_submitted>
  <results_first_submitted_qc>February 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2017</results_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jean-Francois Pittet</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamins C and E</title>
          <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
Vitamin C
Vitamin E</description>
        </group>
        <group group_id="P2">
          <title>0.9% Saline and Sugar Pill</title>
          <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
Saline (for Vitamin C): 0.9% saline administered to mimic Vitamin C
Placebo (for Vitamin E): Sugar pill administered to mimic Vitamin E</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamins C and E</title>
          <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
Vitamin C
Vitamin E</description>
        </group>
        <group group_id="B2">
          <title>0.9% Saline and Sugar Pill</title>
          <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
Saline (for Vitamin C): 0.9% saline administered to mimic Vitamin C
Placebo (for Vitamin E): Sugar pill administered to mimic Vitamin E</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Coagulation Abnormalities</title>
        <description>Coagulation parameters are evaluated using standard functional tests (prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen and platelet count)and point of care functional analysis using thromboelastogram (TEG-ROTEM). A blood sample is collected upon arrival in the emergency department at 0 hours only and analyzed for markers of activation of coagulation, inflammation, and levels of vitamin C/E.</description>
        <time_frame>From enrollment up to 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
Vitamin C
Vitamin E</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
Saline (for Vitamin C): 0.9% saline administered to mimic Vitamin C
Placebo (for Vitamin E): Sugar pill administered to mimic Vitamin E</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Coagulation Abnormalities</title>
          <description>Coagulation parameters are evaluated using standard functional tests (prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen and platelet count)and point of care functional analysis using thromboelastogram (TEG-ROTEM). A blood sample is collected upon arrival in the emergency department at 0 hours only and analyzed for markers of activation of coagulation, inflammation, and levels of vitamin C/E.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Ventilator-associated Pneumonia.</title>
        <description>Number of subjects diagnosed with pneumonia and requiring ventilator support.</description>
        <time_frame>From enrollment to 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Ventilator-associated Pneumonia.</title>
          <description>Number of subjects diagnosed with pneumonia and requiring ventilator support.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Organ Injury</title>
        <description>Any injury to internal organs (thoracic, abdominal or cranial cavity)</description>
        <time_frame>From enrollment to 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Organ Injury</title>
          <description>Any injury to internal organs (thoracic, abdominal or cranial cavity)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Total Blood Product Transfusions</title>
        <description>the number of blood product transfusions for all subjects in each group over the course of 3 days.</description>
        <time_frame>From enrollment to 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Total Blood Product Transfusions</title>
          <description>the number of blood product transfusions for all subjects in each group over the course of 3 days.</description>
          <units>blood transfusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Protocol Violations Per Arm.</title>
        <description>The number of times that there was a deviation or violation from how the protocol was to be implemented.</description>
        <time_frame>from enrollment up to 60 days post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C and E Participants -</title>
            <description># of protocol deviations</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill Participants - Protocol Violations</title>
            <description># of protocol deviations</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Protocol Violations Per Arm.</title>
          <description>The number of times that there was a deviation or violation from how the protocol was to be implemented.</description>
          <units>protocol deviations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Surviving to Day 28</title>
        <description>Number of subjects that survived to day 28 after enrollment</description>
        <time_frame>from enrollment up to 28 days post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Surviving to Day 28</title>
          <description>Number of subjects that survived to day 28 after enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With 60-day Survival</title>
        <description>Number of subjects in each arm that survived to day 60</description>
        <time_frame>from enrollment up to 60 days post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With 60-day Survival</title>
          <description>Number of subjects in each arm that survived to day 60</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Ventilator-free Days for Subjects</title>
        <description>The mean number of ventilator free days (not on ventilator) for subjects in each arm</description>
        <time_frame>from enrollment up to 60 days post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Ventilator-free Days for Subjects</title>
          <description>The mean number of ventilator free days (not on ventilator) for subjects in each arm</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="2" upper_limit="23"/>
                    <measurement group_id="O2" value="6.2" lower_limit="1" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days in ICU.</title>
        <description>the mean number of days each subject was in the ICU in each arm</description>
        <time_frame>from enrollment up to 60 days post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days in ICU.</title>
          <description>the mean number of days each subject was in the ICU in each arm</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="3" upper_limit="30"/>
                    <measurement group_id="O2" value="11" lower_limit="4" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Hospital Stay Days.</title>
        <description>The mean number of days subjects were in the hospital in each arm of the study</description>
        <time_frame>from enrollment up to 60 days post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins C and E</title>
            <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>0.9% Saline and Sugar Pill</title>
            <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Hospital Stay Days.</title>
          <description>The mean number of days subjects were in the hospital in each arm of the study</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="6" upper_limit="39"/>
                    <measurement group_id="O2" value="18.2" lower_limit="6" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse events were collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Vitamins C and E</title>
          <description>Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
Vitamin C
Vitamin E</description>
        </group>
        <group group_id="E2">
          <title>0.9% Saline and Sugar Pill</title>
          <description>100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
Saline (for Vitamin C): 0.9% saline administered to mimic Vitamin C
Placebo (for Vitamin E): Sugar pill administered to mimic Vitamin E</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated--inability to recruit patient that met inclusion criteria.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jean-Francois Pittet, MD</name_or_title>
      <organization>UAB Department of Anesthesiology</organization>
      <phone>205-996-4755</phone>
      <email>jpittet@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

